TISIDB

Summary
Symbol	TAL1
Name	T-cell acute lymphocytic leukemia 1
Aliases	bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00010 Helix-loop-helix DNA-binding domain
Function	Implicated in the genesis of hemopoietic malignancies. It may play an important role in hemopoietic differentiation. Serves as a positive regulator of erythroid differentiation (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0001525 angiogenesis GO:0001672 regulation of chromatin assembly or disassembly GO:0001704 formation of primary germ layer GO:0001707 mesoderm formation GO:0002244 hematopoietic progenitor cell differentiation GO:0002262 myeloid cell homeostasis GO:0002521 leukocyte differentiation GO:0002573 myeloid leukocyte differentiation GO:0002761 regulation of myeloid leukocyte differentiation GO:0006333 chromatin assembly or disassembly GO:0007346 regulation of mitotic cell cycle GO:0007369 gastrulation GO:0007498 mesoderm development GO:0007626 locomotory behavior GO:0010001 glial cell differentiation GO:0019827 stem cell population maintenance GO:0021510 spinal cord development GO:0021515 cell differentiation in spinal cord GO:0021516 dorsal spinal cord development GO:0021527 spinal cord association neuron differentiation GO:0021700 developmental maturation GO:0021781 glial cell fate commitment GO:0021953 central nervous system neuron differentiation GO:0030099 myeloid cell differentiation GO:0030218 erythrocyte differentiation GO:0030219 megakaryocyte differentiation GO:0030220 platelet formation GO:0030221 basophil differentiation GO:0030851 granulocyte differentiation GO:0031334 positive regulation of protein complex assembly GO:0032844 regulation of homeostatic process GO:0032846 positive regulation of homeostatic process GO:0034101 erythrocyte homeostasis GO:0035162 embryonic hemopoiesis GO:0035855 megakaryocyte development GO:0036344 platelet morphogenesis GO:0042063 gliogenesis GO:0043249 erythrocyte maturation GO:0043254 regulation of protein complex assembly GO:0044089 positive regulation of cellular component biogenesis GO:0045165 cell fate commitment GO:0045637 regulation of myeloid cell differentiation GO:0045639 positive regulation of myeloid cell differentiation GO:0045646 regulation of erythrocyte differentiation GO:0045648 positive regulation of erythrocyte differentiation GO:0045787 positive regulation of cell cycle GO:0045799 positive regulation of chromatin assembly or disassembly GO:0045931 positive regulation of mitotic cell cycle GO:0048332 mesoderm morphogenesis GO:0048333 mesodermal cell differentiation GO:0048469 cell maturation GO:0048514 blood vessel morphogenesis GO:0048568 embryonic organ development GO:0048708 astrocyte differentiation GO:0048821 erythrocyte development GO:0048863 stem cell differentiation GO:0048872 homeostasis of number of cells GO:0051302 regulation of cell division GO:0051781 positive regulation of cell division GO:0060018 astrocyte fate commitment GO:0060215 primitive hemopoiesis GO:0060216 definitive hemopoiesis GO:0060217 hemangioblast cell differentiation GO:0060218 hematopoietic stem cell differentiation GO:0060348 bone development GO:0060374 mast cell differentiation GO:0060375 regulation of mast cell differentiation GO:0061515 myeloid cell development GO:0098727 maintenance of cell number GO:0098751 bone cell development GO:1902105 regulation of leukocyte differentiation GO:1902275 regulation of chromatin organization GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:1905269 positive regulation of chromatin organization GO:2000036 regulation of stem cell population maintenance
Molecular Function	GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0001046 core promoter sequence-specific DNA binding GO:0001047 core promoter binding GO:0001085 RNA polymerase II transcription factor binding GO:0001158 enhancer sequence-specific DNA binding GO:0003682 chromatin binding GO:0008134 transcription factor binding GO:0035326 enhancer binding GO:0042826 histone deacetylase binding GO:0046982 protein heterodimerization activity GO:0070888 E-box binding
Cellular Component	GO:0000118 histone deacetylase complex GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0005667 transcription factor complex GO:0033193 Lsd1/2 complex GO:0044454 nuclear chromosome part

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	TAL1
Name	T-cell acute lymphocytic leukemia 1
Aliases	bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TAL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TAL1
Name	T-cell acute lymphocytic leukemia 1
Aliases	bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TAL1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TAL1
Name	T-cell acute lymphocytic leukemia 1
Aliases	bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TAL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.276	0.15
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.409	0.284
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.179	0.577
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.12	0.747
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.1	0.929
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.149	0.907
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.238	0.568
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.397	0.558
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.12	0.864
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.91	0.0277
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.623	0.2
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.281	0.0749

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TAL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TAL1
Name	T-cell acute lymphocytic leukemia 1
Aliases	bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TAL1
Name	T-cell acute lymphocytic leukemia 1
Aliases	bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAL1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TAL1
Name	T-cell acute lymphocytic leukemia 1
Aliases	bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TAL1
Name	T-cell acute lymphocytic leukemia 1
Aliases	bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TAL1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TAL1
Name	T-cell acute lymphocytic leukemia 1
Aliases	bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TAL1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TAL1
Name	T-cell acute lymphocytic leukemia 1
Aliases	bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TAL1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TAL1